4.3 Article

The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia

期刊

ONCOTARGET
卷 6, 期 26, 页码 22734-22749

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4212

关键词

SF3B1; chronic lymphocytic leukemia; sudemycin; ibrutinib; spliceosome

资金

  1. Ministerio de Ciencia e Innovacion Redes Tematicas de Investigacion Cooperativa de Cancer from the Instituto de Salud Carlos III (ISCIII) [SAF 12/31242]
  2. Spanish Ministry of Economy and Competitiveness & European Regional Development Fund (ERDF) Una manera de hacer Europa [RD12/0036/0004, RD12/0036/0036, RD12/0036/0023, RD12/0036/0067]
  3. Generalitat de Catalunya [2014SGR967]

向作者/读者索取更多资源

Mutations or deregulated expression of the components of the spliceosome can influence the splicing pattern of several genes and contribute to the development of tumors. In this context, we report that the spliceosome modulator sudemycin induces selective cytotoxicity in primary chronic lymphocytic leukemia (CLL) cells when compared with healthy lymphocytes and tumor cells from other B-lymphoid malignancies, with a slight bias for CLL cases with mutations in spliceosome-RNA processing machinery. Consistently, sudemycin exhibits considerable antitumor activity in NOD/SCID/IL2R gamma(-/-) (NSG) mice engrafted with primary cells from CLL patients. The antileukemic effect of sudemycin involves the splicing modulation of several target genes important for tumor survival, both in SF3B1-mutated and -unmutated cases. Thus, the apoptosis induced by this compound is related to the alternative splicing switch of MCL1 toward its proapoptotic isoform. Sudemycin also functionally disturbs NF-kappa B pathway in parallel with the induction of a spliced RELA variant that loses its DNA binding domain. Importantly, we show an enhanced antitumor effect of sudemycin in combination with ibrutinib that might be related to the modulation of the alternative splicing of the inhibitor of Btk (IBTK). In conclusion, we provide first evidence that the spliceosome is a relevant therapeutic target in CLL, supporting the use of splicing modulators alone or in combination with ibrutinib as a promising approach for the treatment of CLL patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据